High purity amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 6, 2007, Pages 1331-1340

  Cleary, John D ^a   Chapman, Stanley W ^a   Swiatlo, Edwin ^a   Kramer, Robert ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungals; Mycology; Polyenes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; APOTHECON; CALCIUM; CYTOKINE; DNA; GENERIC DRUG; POLYENE; THYMIDINE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CANDIDA ALBICANS; CANDIDIASIS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSOLIC FRACTION; DNA SYNTHESIS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG ISOLATION; DRUG PURITY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD 50; LOW DRUG DOSE; MONOCYTE; MOUSE; MYCOSIS; NEPHROTOXICITY; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUGS, GENERIC; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MONOCYTES; POLYENES; RATS; RATS, SPRAGUE-DAWLEY; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 36448941209     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm322     Document Type: Article

References (21)

1. Cleary JD, Kramer R, Swiatlo E et al. Improved safety and efficacy with amphotericin B HP (AmB HP). In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract F-498, p. 182. American Society for Microbiology, Washington, DC, USA.
2. National Committee for Clinical Laboratory Standards. Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. Villanova, PA, USA: NCCLS, 1997.
3. Kramer RE. Angiotensin II-stimulated changes in calcium metabolism in cultured bovine glomerulosa cells. Mol Cell Endocrinol 1988; 60 199-210.
4. Kramer RE. Angiotensin II causes sustained elevations of cytosolic calcium in glomerulosa cells. Am J Physiol 1988; 255: E338.
5. Rogers PD, Kramer RE, Chapman SW et al. Calcium-mediated signal transduction of amphotericin B-induced interleukin-1β expression in human monocytic cells. J Inf Dis 1999; 180: 1259-66.
6. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
7. Gellai M, Valtin H. Chronic vascular constrictions and measurements of renal function in conscious rats. Kidney Int 1979; 15: 419-26.
8. Cleary JD, Rogers PD, Chapman SW. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy 2003; 23: 572-8.
9. Goodwin SD, Cleary JD, Walawander CA et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755-61.
10. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
11. Wey SB, Mori M, Pfaller MA et al. Risk factors for hospital-acquired candidernia. A matched case-control study. Arch Intern Med 1989; 149: 2349-53.
12. Cleary JD, Nolan RL, Chapman SW. Inhibition of intedeukin 1 release from endotoxin or amphotericin B stimulated monocytes. Antimicrob Agents Chemother 1992; 36: 977-81.
13. Rogers PD, Jenkins JK, Chapman SW et al. Amphotericin B activation of human genes encoding for cytokines. J Inf Dis 1998; 178: 1726-33.
14. Luber AD, Mae L, Lam M et al. Risk factors for AmB-induced nephrotoxicity. J Antimicrob Chemother 1999; 43: 267-71.
15. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476-83.
16. Harbarth S, Burke JP, Lloyd JF et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002; 35: E120-e127.
17. Ostrosky-Zeichner L, Marr KA, Rex JH et al. Amphotericin B: Time for a new 'Gold Standard'. Clin Infect Dis 2003; 37: 415-25.
18. Novak J, Reckelhoff J, Bumgamer L et al. Reduced sensitivity of the renal circulation to angiotensin II in pregnant rats. Hypertension 1997; 30: 580-4.
19. Chavanet P, Joly V, Rigaud D et al. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob Agents Chemother 1994; 38: 963-8.
20. Mitsutake K, Kohno S, Miyazaki Y et al. In vitro and in vivo anti-fungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 1994; 128: 13-7.
21. Bennett JE, Hill GJ, Butler WT et al. Correlation of particle size of intravenous amphotericin B with toxic and chemotherapeutic effects. Antimicrob Agents Chemother 1963; 161: 745-52.